Crescendo Bioscience Announces Six Studies with Vectra® DA Will Be Presented at the 2017 Annual European Congress of Rheumatology

Clinical Utility of Vectra® DA Further Demonstrated with New Data on Prediction of Joint Damage

SALT LAKE CITY, June 8, 2017 – Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that new data on the use of the Vectra® DA test will be presented at the European League Against Rheumatism (EULAR) meeting being held June 14-17, 2017, in Madrid.  Vectra DA is the only multi-biomarker blood test proven to measure disease activity and predict joint damage progression in patients with rheumatoid arthritis in a number of clinical studies.

“We are excited to present several new studies, several of which were done in collaboration with our academic partners, at this year’s EULAR meeting.  We continue to expand the body of clinical data supporting Vectra DA and demonstrate the clinical utility of the test,” said Elena Hitraya, M.D., Ph.D., chief medical officer, Crescendo Bioscience.  “The rheumatology community is taking great interest in biomarkers and their ability to help personalize treatment plans and achieve better health outcomes for their patients with RA.”

A list of the Vectra DA presentations at EULAR 2017 is below.  Follow Vectra DA on Twitter via @VectraDA and Myriad via @MyriadGenetics to stay informed about symposium news and updates by using the hashtag #EULAR2017.

 

 

Title

 

Author

Poster Number  

Day/Time

 

Poster Session

Vectra DA Podium Presentation

Multi-Biomarker Disease Activity and Autoantibody Status Lead To Cost Effective Tapering Algorithms in Rheumatoid Arthritis Patients in Sustained Remission

 

 

 

Vectra DA Poster Presentations

 

M. Hagen OPO249 Friday, June 16, 2017:

10:15 a.m. – 11:45 a.m.

CEST.

 

RA – Causes and Courses
Daily and Diurnal Variation and Determination of the Minimally Important Difference in Rheumatoid Arthritis Patients with Moderate to High Multi-Biomarker Disease Activity Scores (MID) David Chernoff THU0087 Thursday, June 15, 2017: 11:45 a.m. – 1:30 p.m. CEST.

 

Session I
High multi-biomarker disease activity score is associated with high risk of radiographic progression in six studies (Meta-Analysis) Eric Sasso THU0091 Thursday, June 15, 2017: 11:45 a.m. – 1:30 p.m. CEST.

 

Session I
Determining Minimum Clinically Important Change in Multi Biomarker Disease Activity Score Associated with Clinical Improvement in Methotrexate Naïve Patients with Early Rheumatoid Arthritis (EIRA)

 

Katerina Chatzidionysiou FRI0100 Friday, June 16, 2017: 11:45 a.m. – 1:30 p.m. CEST. Session II
Multi-biomarker disease activity (MBDA) is associated with the progression of structural bone damage in rheumatoid arthritis patients in remission  G. Schett THU0096 Thursday, June 15, 2017: 11:45 a.m. – 1:30 p.m. CEST.

 

Session I
 

Elevated multi-biomarker disease activity (MBDA) predicts relapse in RA patients in sustained remission tapering tumour necrosis factor inhibitor therapy- Results from the randomized controlled RETRO study

 

J. Rech

 

FRI0098

 

Friday, June 16, 2017:

11:45 a.m. – 1:30 p.m.

CEST.

 

Session II

The efficacy of Vectra DA has been proven in more than 35 studies with more than 3,000 patients. The clinical utility for Vectra DA has been widely recognized as three out of four rheumatologists have used Vectra DA and have ordered it for more than 300,000 patients in the United States.  Recently, Vectra DA was included in guidelines published by United Rheumatology and will be evaluated for inclusion in the American College of Rheumatology (ACR) guidelines.  Additionally, Creaky Joints, a leading advocacy group for patients with RA added Vectra DA to its professional guidelines, which underscores the importance of Vectra DA to the patient community.

For more information about these presentations, including a complete list of abstracts and presentations, please visit the EULAR website at http://www.congress.eular.org/.

About Vectra® DA

Vectra DA is the only multi-biomarker blood test for rheumatoid arthritis disease activity that integrates the concentrations of 12 serum proteins associated with RA disease activity into a single objective score, on a scale of 1 to 100, to help physicians make more informed treatment decisions. Vectra DA testing is performed at the Crescendo Bioscience state-of-the-art CLIA (Clinical Laboratory Improvement Amendments) facility. Test results are reported to the physician 5 to 7 days from shipping of the specimen to Crescendo Bioscience. Physicians can receive test results via standard mail, by fax or via the private web portal, VectraView. For more information on Vectra DA, please visit: www.Vectra-DA.com.

About Crescendo Bioscience

Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc., is a molecular diagnostics company dedicated to developing and commercializing quantitative blood tests for rheumatoid arthritis (RA) and other autoimmune diseases, located in South San Francisco, Calif.  Crescendo Bioscience develops quantitative, objective, reproducible blood tests to provide rheumatologists with deeper clinical insight to help enable more effective management of patients with autoimmune and inflammatory diseases.  For more information, please visit the company website at www.CrescendoBio.com.

About Myriad Genetics

Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics.  Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs.  Myriad is focused on three strategic imperatives:  transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets.  For more information on how Myriad is making a difference, please visit the Company’s website: www.myriad.com.

Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, Vectra, Prolaris EndoPredict and GeneSight are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G

Safe Harbor Statement

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the Vectra DA data to be presented at the 2017 Annual European Congress of Rheumatology (EULAR) Annual Meeting, June 14-17, 2017 in Madrid.; the potential clinical utility of the Vectra DA study results and findings for guiding treatment decisions in patients with RA;  and the Company’s strategic directives under the captions “About Crescendo Bioscience” and “About Myriad Genetics.” These “forward-looking statements” are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that sales and profit margins of our molecular diagnostic tests and pharmaceutical and clinical services may decline; risks related to our ability to transition from our existing product portfolio to our new tests, including unexpected costs and delays; risks related to decisions or changes in governmental or private insurers’ reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services and any future tests and services are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities and our healthcare clinic; risks related to public concern over genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire; risks related to our projections about our business, results of operations and financial condition; risks related to the potential market opportunity for our products and services; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents or other intellectual property; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decision in the lawsuit brought against us by the Association for Molecular Pathology et al; risks of new, changing and competitive technologies and regulations in the United States and internationally; and other factors discussed under the heading “Risk Factors” contained in Item 1A of our most recent Annual Report on Form 10-K for the fiscal year ended June 30, 2016, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K.  All information in this press release is as of the date of the release, and Myriad undertakes no duty to update this information unless required by law.

###